167 related articles for article (PubMed ID: 38342727)
21. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
22. Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
Ghorashian S; Amrolia P; Veys P
Exp Hematol; 2018 Oct; 66():5-16. PubMed ID: 30031849
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
Front Immunol; 2021; 12():665230. PubMed ID: 33953727
[TBL] [Abstract][Full Text] [Related]
24. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
[TBL] [Abstract][Full Text] [Related]
25. Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients.
Hall AG; Winestone LE; Sullivan EM; Wu Q; Lamble AJ; Walters MC; Aguayo-Hiraldo P; Baez Conde L; Coker TR; Dornsife D; Keating AK; Merino DM; Ramsey B; Park JR; Agrawal AK
Transplant Cell Ther; 2023 Jun; 29(6):356.e1-356.e7. PubMed ID: 36966871
[TBL] [Abstract][Full Text] [Related]
26. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
[TBL] [Abstract][Full Text] [Related]
27. CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.
Gambella M; Carlomagno S; Raiola AM; Giannoni L; Ghiggi C; Setti C; Giordano C; Luchetti S; Serio A; Bo A; Falco M; Della Chiesa M; Angelucci E; Sivori S
Front Immunol; 2022; 13():837457. PubMed ID: 35280988
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis.
Cao HH; Wang LL; Geng CK; Mao WW; Yang LL; Ma Y; He M; Zhang R; Zhou YY; Liu LQ; Hu XJ; Yu JX; Yang L; Shen XF; Yin LF; Gu XZ; Shen ZL
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4921-4930. PubMed ID: 32432755
[TBL] [Abstract][Full Text] [Related]
29. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
30. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
31. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Yuen C; Rezania K; Kelly T; Bishop MR
Immunotherapy; 2021 Oct; 13(15):1261-1269. PubMed ID: 34558978
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
33. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
Mondello P; Nowakowski GS
Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
36. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
[TBL] [Abstract][Full Text] [Related]
37. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
38. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
39. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
40. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]